Drugs / 9MW0813
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05324592 | Feb → Sep 2021 | diabetic macular edema | Mabwell (Shanghai) Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05324774 | Feb 2022 → Sep 2023 | diabetic macular edema | Mabwell (Shanghai) Bioscience Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 9MW0813 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05324774 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human vascular endothelial growth factor receptor-antibody fusion protein” NCT05324592 ↗ |
| Route | Intravitreal | “single intravitreal injection (IVT) of 9MW0813 injection” NCT05324592 ↗ |